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What is already known?
 Current CHF management guidelines recommend evidence-
based treatment and care-modalities. Moreover, there is an
emphasis on patient rehabilitation that acknowledge the
need for improvement in patient health-related outcome.
Add-on therapies based on Ayurveda and/or herbal treatment
are known to have the potential to address this lacunae.
What this study adds?
 Present study introduces HFRT, an add-on therapy to SCT that
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Objectives: The present study was designed to evaluate effect of heart failure reversal therapy (HFRT)
using herbal procedure (panchakarma) and allied therapies, as add-on to standard CHF treatment (SCT) in
chronic heart failure (CHF) patients.
Methods: This open-label, randomized study conducted in CHF patients (aged: 25–65 years, ejection
fraction: 30–65%), had 3-phases: 1-week screening, 6-week treatment (randomized [1:1] to HFRT + SCT
or SCT-alone) and follow-up (12-week). Twice weekly HFRT (60–75 min) consisting of snehana (external
oleation), swedana (passive heat therapy), hrudaydhara (concoction dripping treatment) and basti
(enema) was administered. Primary endpoints included evaluation of change in metabolic equivalents of
task (MET) and peak oxygen uptake (VO2peak) from baseline, at end of 6-week treatment and follow-up at
week-18 (non-parametric rank ANCOVA analysis). Safety and quality of life (QoL) was assessed.
Results: Seventy CHF patients (n = 35, each treatment-arm; mean [SD] age: 53.0 [8.6], 80% men) were
enrolled in the study. All patients completed treatment phase. Add-on HFRT caused a signiﬁcant increase
in METs (least square mean difference [LSMD], 6-week: 1.536, p = 0.0002; 18-week: 1.254, p = 0.0089)
and VO2peak (LSMD, 6-week: 5.52, p = 0.0002; 18-week: 4.517, p = 0.0089) as compared with SCT-
alone. Results were suggestive of improved functional capacity in patients with HFRT (QoL; Mean [SD]
HFRT + SCT vs. SCT-alone; 6-week: 0.44 [0.34] vs. 0.06 [0.25], p < 0.0001 and 18-week: 0.53 [0.35]
vs. 0.29 [0.26], p = 0.0013). Seven treatment-emergent adverse events (mild severity) were reported in
HFRT-arm.
Conclusion: Findings of this study highlight therapeutic efﬁcacy of add-on HFRT vs. SCT-alone in CHF
patients. The non-invasive HFRT showed no safety concerns.
 2016 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
§ Registration: Clinical Trials Registry of India registration number: CTRI/2015/
01/005384.
* Corresponding author.
E-mail address: drrahul@madhavbaug.org (R. Mandole).
Abbreviations: 2D-ECHO, two dimensional-echocardiogram; ACE, angiotensin
converting enzyme; ANCOVA, analysis of covariance; ARBs, angiotensin receptor
blockers; CHF, chronic heart failure; DPP, double pressure product; ECG,
electrocardiography; EF, ejection fraction; FAS, Full Analysis Set; IHD, Ischemic
Heart Disease; HFRT, heart failure reversal therapy; HRR, heart rate recovery; LSMD,
least square mean difference; MET, metabolic equivalents of tasks; NYHA, New York
Heart Association; PLBS, post lunch blood sugar; PP, Per Protocol Set; QoL, quality of
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The management of chronic heart failure (CHF) is a topic,
broadly discussed since eons, and has well-established treatment
regimens emphasizing the goal of reduction in symptoms and
improvement of prognosis. The worldwide growing prevalence of
CHF shows an annual incidence of 0.5–1.8 million in India.1 As a
result, plethora of research is performed to identify newer
therapeutic targets for better management of CHF.2 A contempo-
rary physician is mindful of crucial objective of maximizing
function in everyday life and strives to achieve the highest level of
quality of life (QoL) within the limitations imposed by the disease.
Along with symptoms of CHF, an array of undesirable emotions
including fear and anxiety of health status lead to deterioration in
the patient’s morale and a progressive decline in QoL. Despite
improvement in therapeutic drugs and devices, CHF has poor
prognosis. The critical therapeutic advantages are those that
maintain and stabilize the patient’s limited functional abilities and,
also improve the comfort of the patient for remaining life-span.3
The standard CHF treatment (SCT) includes b-blockers,
angiotensin-converting enzyme (ACE) inhibitors, angiotensin II
receptor blockers (ARBs), digoxin, anti-platelets and diuretics.4
However, majority of CHF patients require complex management
due to growing age, comorbidities, multiple medications, and
depression or reduced coping skills.5 Considering these exigencies,
a search is ongoing for preferably non-invasive add-on therapies
with SCT. Historical data have reported that b-blockers, ARBs have
antioxidant, and/or anti-inﬂammatory properties, which may
attribute to their therapeutic effects.6,7 Several herbs are known
to possess antioxidant, anti-inﬂammatory, antiplatelet or hypoli-
pidemic properties.8–14 It would, therefore, be interesting to
explore if these herbs have an additional cardioprotective effect in
CHF patients.
Ayurvedic physicians advocate use of conventional treatment
in the acute disease phase and in chronic condition subsequent use
of panchakarma therapy (a 5-step procedure for internal puriﬁca-
tion of the body) as an add-on, for providing maximum beneﬁt to
the patient.15 Heart failure reversal therapy (HFRT) formerly
known, sampurna hruyday shudhikaran (SHS) therapy is a
combination of herbal treatment with panchakarma and allied
therapies.16–18 The techniques used in panchakarma namely
snehana (massage), swedana (fomentation therapy) and basti
(type of enema) are known to eliminate toxins.15,19
The primary objective of this randomized, open-label, compar-
ative study was to evaluate the effect of HFRT as an add-on therapy
to SCT on metabolic equivalents of tasks (METs) and peak oxygen
uptake (VO2peak) in CHF patients. The effect on ejection fraction
(EF), time to onset of ischemia (TOI), double pressure product
(DPP), heart rate recovery (HRR) and quality of life (QoL) were also
evaluated.
2. Methods
2.1. Study population
Study participants included patients (both gender, aged 25–65
years) with CHF (New York Heart Association, NYHA Class I–III),
history of CHF irrespective of angioplasty and coronary artery
bypass graft on SCT, having MET values: 3–7 (inclusive), and EF
between 30–65% (inclusive) on a standard two dimensional-
Echocardiogram (2D-ECHO) test (6 months prior to screening).
Additional inclusion criteria were systolic blood pressure not
>150 mmHg and diastolic blood pressure not >90 mmHg,
hemoglobin levels 10 g/dL, blood sugar level (fasting not
<60 mg/dL and PLBS not >250 mg/dL).Please cite this article in press as: Sane R, et al. Effect of heart failure re
failure: A randomized, open-label study, Indian Heart J. (2016), httpPatients with suspected hypersensitivity to study therapy,
acute heart failure, decompensated heart failure attack (last 3-
months), irritable bowel syndrome, bleeding piles or ﬁstula (grade-
I or II piles), 2nd/3rd degree hemorrhoids, asthma or chronic
obstructive pulmonary disease, abnormal thyroid function test,
hepatic or renal insufﬁciency, cancer, physical disability (any form)
leading to immobilization, participation in another study 30-days
prior to screening were excluded. Patients not on stable dose of SCT
(last 3-months), needing upward dose titration were excluded and
also pregnant or lactating women.
The Independent Ethics Committee approved the protocol. The
study was conducted in accordance with the ethical principles in
the Declaration of Helsinki, consistent Good Clinical Practices, and
applicable regulatory requirements. All patients or their legally
acceptable representatives provided written informed consent to
participate in the study.
2.2. Study design
Open-label, randomized study, conducted from 2014 to
2015 in outpatients at two centers (Bhaktivedanta Hospital,
Mumbai and Shree Saibaba Heart Institute and Research Center,
Nasik) was divided into 3-phases: screening (up to 1-week),
treatment (6-week) and follow-up phase (12-week). At treat-
ment phase, patients enrolled after screening were randomized
(1:1) to either groups: (1) HFRT, twice/week plus SCT (like
b-blockers, ACE inhibitors, digoxin, anti-platelets and diuretics)
or (2) SCT-alone. Randomized and treated patients were
evaluated at end of the treatment (6-week) and at 18-week in
the follow phase (Fig. 1).
Permuted block randomization was performed to allot either
treatment: HFRT + SCT or SCT-alone based on next available
number as per the randomization chart.
2.3. Study therapy
The HFRT, a 4-step procedure (snehana, swedana, hrudaydhara,
basti) requiring 65–75 min was performed after a light breakfast
(Fig. 2; Supplementary material15,19).
2.4. Study evaluations
2.4.1. Cardiac function measures
Primary endpoints were improvement in MET and VO2peak as
evaluated by cardiac stress test with modiﬁed Bruce protocol and
12-lead electrocardiography (ECG) at baseline, 6 and 18-week.
MET is ratio of metabolic rate (the rate of energy consumption)
during a speciﬁc physical activity to a reference metabolic rate
(3.5 ml O2 kg
1 min1). VO2peak is the measurement of the volume
of oxygen that the body can utilize during physical exertion
(VO2max = MET value  3.6).
Secondary endpoints (monitored at 6 and 18-week) included
improvement in QoL: assessed by questionnaires (adapted from
validated questionnaires20–23), EF, improvement in TOI and DPP
and HRR as assessed by monitoring heart rate.
HRR is time taken to return to normal heart rate at end of stress
test. TOI (time to onset 1 mm of ST segment change in more than
2 leads) and DPP (product of maximum heart rate and systolic
blood pressure) were recorded during stress test.
2.4.2. Safety and tolerability
Safety was assessed throughout the study and evaluated by
frequency, severity and intensity of treatment-emergent adverse
events (TEAEs), serious TEAEs, physical examinations, vital signs
and laboratory tests (biochemistry, hematology, and urine
analysis).versal treatment as add-on therapy in patients with chronic heart
://dx.doi.org/10.1016/j.ihj.2016.10.012
Fig. 1. Study design and patient ﬂow.
Fig. 2. Study therapy.
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2.5.1. Analysis set
Analysis sets were as follows: Safety Set (SS) randomized
patients who received treatment at least once; Full Analysis Set
(FAS) – patients who had primary efﬁcacy parameters assessed
post-baseline; Per Protocol Set (PP) – patients who completed the
study with no protocol deviations.
2.5.2. Sample size determination
The sample size (N = 27, each treatment group) was pre-
speciﬁed to the minimal detectable differences of 1.5 in MET
and 3.0 in VO2peak levels (mean change from baseline) between
the two treatment groups at week 12 with 80% power and
a 0.05, two-sided signiﬁcance level and standard deviation
of 1.9 in MET and 3.8 in VO2peak levels. Assuming 20%
dropout rate, 35 CHF patients were required to be enrolled in
each group.Please cite this article in press as: Sane R, et al. Effect of heart failure re
failure: A randomized, open-label study, Indian Heart J. (2016), http2.5.3. Statistical analyses
Demographic and baseline characteristics of SS were summa-
rized descriptively. The mean change in efﬁcacy endpoints
between groups was analyzed using non-parametric rank analysis
of covariance (ANCOVA), with baseline values as covariates.
Wilcoxon Rank Sum test was used to compare QoL data. Statistical
analyses were performed using SAS software version 9.2 (SAS
Institute Inc., USA).
3. Results
3.1. Study population
Total 70/76 screened CHF patients were enrolled and random-
ized in open-label treatment-phase to either groups: HFRT + SCT
(n = 35, 50%) or SCT-alone (n = 35, 50%). The study population
(mean [SD] age: 53.0 [8.6]) comprised of 80% men (HFRT + SCT
group, n = 27 [77%]; SCT-alone group, n = 29 [83%]). The baselineversal treatment as add-on therapy in patients with chronic heart
://dx.doi.org/10.1016/j.ihj.2016.10.012
Table 1
Baseline and clinical characteristics (Safety Set).
Parameters HFRT + SCT
(N = 35)
SCT alone
(N = 35)
Total
(N = 70)
Age, years
Mean (SD) 53.5 (8.1) 52.5 (9.1) 53.0 (8.6)
Men, n (%) 27 (77) 29 (83) 56 (80)
Baseline weight, (kg)
Mean (SD) 67 (11.3) 69 (13.1) 68 (12.1)
Smoking, n (%)
Yes 1 (3) 1 (3) 2 (3)
Tobacco consumption, n (%)
Yes 1 (3) 1 (3) 2 (3)
Alcohol consumption, n (%)
Yes 3 (9) 4 (11) 7 (10)
History of allergy, n (%)
Yes 0 1 (3) 1(1)
Medical history, n (%)
Hypertension 18 (51) 19 (54) 37 (53)
Diabetes 8 (23) 12 (34) 20 (29)
Hypercholesterolemia 2 (6) 2 (6) 4 (6)
Intervention
PTCA 11 (31) 12 (34) 23 (33)
NYHA Class, n (%)
I 9 (26) 5 (14) 14 (20)
II 25 (71) 30 (86) 55 (79)
III 1 (3) 0 1 (1)
Concomitant medicines, n (%)
Anti-platelets drugs 15 (43) 17 (49) 33 (47)
NSAIDs 5 (14) 5 (14) 10 (14)
Statins 5 (14) 5 (14) 10 (14)
b-Blockers 3 (9) 3 (9) 7 (10)
HFRT, heart failure reversal therapy; NSAID, non-steroidal anti-inﬂammatory drug;
NYHA, New York Heart Association; PTCA, percutaneous transluminal coronary
angioplasty; SCT, standard chronic heart failure treatment.
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tween the groups (Table 1).
All randomized patients completed the 6-week treatment-
phase in both groups. A total of 34 (97%) patients in HFRT + SCT and
30 (86%) in SCT-alone group completed the follow-up (Fig. 1).
3.2. Efﬁcacy measurements
Efﬁcacy parameters were analyzed at 6 and 18-week. Patients
in HFRT + SCT group showed signiﬁcant improvement in MET and
VO2peak values from baseline, at 6-week (least square mean
difference [LSMD], MET: 1.536, p = 0.0002; VO2peak: 5.52,
p = 0.0002) and 18-week (LSMD, MET: 1.254, p = 0.0089; VO2peak:
4.517, p = 0.0089) as compared to SCT-alone group. The percent
change for MET and VO2peak values was higher in HFRT + SCT vs.
SCT-alone group from baseline, at 6-week (MET: 45.33 vs. 15.44;
VO2peak: 45.34 vs. 15.49) and 18-week (MET: 51.48 vs. 26.03;
VO2peak: 51.49 vs. 26.03). Results obtained from PP population
conﬁrmed ﬁndings from FAS population (Table 2).
QoL improved signiﬁcantly from baseline (Mean [SD]
HFRT + SCT vs. SCT-alone at 6-week: 0.44 [0.34] vs. 0.06
[0.25], p < 0.0001 and 18-week: 0.53 [0.35] vs. 0.29 [0.26],
p = 0.0013). At 6-week, TOI (LSMD: 97.202, p = 0.002) and DPP
(LSMD: 2242.404, p = 0.0116) was improved signiﬁcantly from
baseline in HFRT + SCT as compared to SCT-alone group. However,
the values were not statistically signiﬁcant at 18-week. The EF was
signiﬁcantly improved from baseline, at 18-week (LSMD: 3.205,
p = <0.0001) in patients of HFRT + SCT as compared with SCT-alone
group (Table 2).Please cite this article in press as: Sane R, et al. Effect of heart failure re
failure: A randomized, open-label study, Indian Heart J. (2016), http3.3. Safety and tolerability
Total 15 TEAEs in either treatment group (HFRT + SCT:
n = 7 [20%] and SCT-alone: n = 8 [23%]) were reported with mild
severity and resolved by end of the study. The TEAEs were mainly
of cardiac or respiratory organ class. One death was reported in the
SCT group during follow-phase (Table 3).
Overall, no TEAEs of abnormal laboratory results, vital signs, or
ECG values were reported from baseline to follow-up.
4. Discussion
This randomized, open-label study of HFRT as add-on therapy
for CHF management, yielded signiﬁcant improvements in MET
and VO2peak values in comparison with SCT-alone, from baseline to
6-week. Interestingly, the improved status was maintained even
12-weeks after the therapy. Signiﬁcant improvements in second-
ary endpoints, EF and QoL were also demonstrated in HFRT treated
patients. Furthermore, the HFRT group showed a better safety
proﬁle vs. SCT-alone.
The CHF patients have a decreased rate of O2 uptake compared
to healthy individuals, leading to fatigue and slow recovery after
exertion. Therefore improvement in VO2peak; a validated indicator
of O2 uptake can help to improve CHF prognosis.
24 Consistent with
our results, increased VO2peak in CHF patients was noted in other
studies, although the intervention was different.25,26 Further, our
observations of enhanced MET from baseline to 18-week are
corroborated by another report evaluating the relationship
between exercise volume and clinical events in CHF patients
wherein 3–7 MET showed a clinical beneﬁt.27 Previous studies
conducted for HFRT (or SHS) also showed improvement in MET and
VO2peak values.
18
A retrospective study in coronary heart disease patients
reported that 1-unit (mL/kg/min) increase in VO2peak is
associated with 15% decrease in risk of death.28 A patient’s
capacity for exercise as measured by VO2peak was thus considered
as a strong predictor of mortality. In the current study, a
signiﬁcant enhancement of VO2peak by 45.34% at the end of HFRT
therapy possibly reﬂects a decline in the risk of mortality in CHF
patients.
The CHF patients experience a progressive decline in QoL as
their ability to perform routine physical activities is compromised
due to early onset of dyspnea and fatigue. Exercise training is
known to substantially increase VO2peak and MET and is currently
recommended to improve QoL in these patients as they become
more tolerant to exertion, experience less fatigue and dyspnea and
become comfortable in performing routine activities.29–31 The
signiﬁcantly enhanced QoL post HFRT reﬂected a remarkable
improvement in these features, sleep pattern, memory and routine
lifestyle. The 4-elements of the HFRT treatment: Snehana, Swedana,
Hrudaydhara and Basti mostly act in cohesion to alleviate the
detrimental effects of CHF. The improvement in QoL with HFRT
treatment by 6-week was maintained till 12-weeks after
treatment. In a retrospective-cohort study in CHF patients, SHS
therapy caused a remarkable improvement from NYHA Class II and
III to Class I in 72% patients.18
The TOI and DPP are associated with Ischemic Heart Disease
(IHD). The HFRT was efﬁcacious with respect to these parameters
for 6-week but not in long-term. Therefore, the role of HFRT in IHD
treatment requires further investigation. HRR is an effective
prognosis parameter at constant workload and MET-value. In this
study, workload and MET-values were variable and hence, HRR
could not be a reliable measure. This explains the erratic HRR
results obtained in both arms of the study.
Although this study had a small sample size, there was 100%
compliance in both treatment arms and the protocol deviationsversal treatment as add-on therapy in patients with chronic heart
://dx.doi.org/10.1016/j.ihj.2016.10.012
Table 3
Treatment-emergent adverse events (Safety Set).
HFRT + SCT SCT alone
N = 35 N = 35
n (%) n (%)
Number of patients
With at least one TEAE 5 (14.3) 2 (5.7)
With at least one severe TEAE 0 2 (5.7)
With at least one serious TEAE 0 2 (5.7)
TEAEs
Lower respiratory tract infection 1 (2.9) 0
Upper respiratory tract infection 1 (2.9) 0
Pain in cubital fossa 1 (2.9) 0
Dengue fever 1 (2.9) 0
Chest pain 1 (2.9) 0
Cough 0 1 (2.9)
Hemoptysis 0 1 (2.9)
Breathlessness 0 1 (2.9)
Breathlessness secondary to
cardio-myopathy with left
ventricular failure
0 1 (2.9)
Dysphagia 0 1 (2.9)
Elevated hypertension 1 (2.9) 0
Vertigo 0 1 (2.9)
Weakness 1 (2.9) 0
Serious TEAE
Death 0 1 (2.9)
HFRT, heart failure reversal therapy; SCI, standard chronic heart failure treatment;
TEAE, treatment-emergent adverse event.
Table 2
Analysis of change from baseline in study parameters (Full Analysis Set).
Parameters HFRT + SCT SCT alone LS mean change
between groupsa
95% CI ANCOVA
p-value
Non-parametric
rank ANCOVA
p-value
LS mean CFB (SE) 95% CI LS Mean CFB (SE) 95% CI
N = 34 N = 33
Week-6
METs 2.33 (0.27) 1.78, 2.88 0.79 (0.28) 0.23, 1.35 1.54 2.32, 0.75 0.0002 <0.0001
VO2peak 8.38 (0.99) 6.40, 10.35 2.86 (1.00) 0.85, 4.86 5.52 8.34, 2.70 0.0002 0.0001
TOI 200.41 (21.09) 158.29, 242.54 103.21 (21.41) 60.45, 145.97 97.20 157.50, 36.90 0.002 0.0016
DPP 1977.51 (604.1) 770.68, 3184.35 264.89 (613.24) 1489.98, 960.20 2242.40 967.16, 517.65 0.0116 0.016
HRR 24.25 (16.48) 8.67, 57.17 24.29 (16.73) 57.70, 9.13 48.54 95.46, 1.62 0.0428 0.0695
QoL Mean (SD) Mean (SD) <0.001
0.44 (0.34) 0.06 (0.25)
Parameters LS Mean CFB (SE) 95% CI LS Mean CFB (SE) 95% CI LS Mean Change
between groupsa
95% CI ANCOVA
p-value
Non-parametric
rank ANCOVA
p-value
N = 34 N = 30
Week-18
METs 2.63 (0.32) 2.0, 3.27 1.38 (0.34) 0.70, 2.05 1.25 2.18, 0.33 0.0089 0.0016
VO2peak 9.48 (1.14) 7.20, 11.77 4.96 (1.22) 2.53, 7.40 4.52 7.86, 1.18 0.0089 0.0016
TOI 3.28 (0.48) 2.33, 4.24 0.08 (0.51) 0.94, 1.10 3.21 4.64, 1.77 <0.0001 <0.0001
DPP 194.68 (25.34) 144.01, 245.35 134.73 (26.98) 80.78, 188.68 59.95 134.08, 14.19 0.111 0.0608
HRR 2236.71 (807.92) 621.17, 3852.24 474.33 (860.49) 1246.33, 2194.99 1762.38 4131.25, 606.50 0.142 0.0694
26.87 (15.6) 4.33, 58.07 18.55 (16.61) 14.67, 51.77 8.33 53.93, 37.28 0.7164 0.984
QoL Mean (SD) Mean (SD) 0.013
0.53 (0.35) 0.29 (0.26)
a LS Mean change between groups is calculated as SCT-alone – HFRT + SCT.
ANCOVA, analysis of covariance; CFB, change from baseline; CI, conﬁdence interval; DPP, double pressure product; HRR, heart rate recovery; HFRT, heart failure reversal
therapy; LS mean, least square mean, MET, metabolic equivalents of task; QoL, quality of life; TOI, time to ischemic onset; VO2peak, peak oxygen uptake.
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size and long-term follow-up in patients with different levels of
CHF severity can shed more light on understanding this novel
treatment option.
5. Conclusion
Add-on therapy with HFRT demonstrated signiﬁcant therapeu-
tic effects with improvement in METs, oxygen uptake and cardiac
measures as compared with SCT-alone and no safety concernsPlease cite this article in press as: Sane R, et al. Effect of heart failure re
failure: A randomized, open-label study, Indian Heart J. (2016), httpwere observed. The HFRT therapy augments the beneﬁcial effects
of SCT thereby improving the exercise tolerance, aerobic capacity,
prognosis and QoL of CHF patients. Hence, the non-invasive HFRT
therapy can be a viable option for planning the modus operandi for
better CHF management
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